MAPT and Alzheimer disease: The levels of plasma LDL, CSF t‐tau, and p‐tau 181 from the APOE ε4 carrier group were significantly higher than that from the non‐carrier group in AD patients (p = 0.015, p = 0.001, p = 0.001) (Table 2, Figure 3).